Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling

Tuberculosis remains the leading cause of death among people living with HIV. Rifapentine is increasingly used to treat active disease or prevent reactivation, in both cases given either as weekly or daily therapy. However, rifapentine is an inducer of CYP3A4, potentially interacting with antiretrov...

Descripción completa

Detalles Bibliográficos
Autores principales: Grañana-Castillo, Sandra, Montanha, Maiara Camotti, Bearon, Rachel, Khoo, Saye, Siccardi, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797969/
https://www.ncbi.nlm.nih.gov/pubmed/36588698
http://dx.doi.org/10.3389/fphar.2022.1076266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797969/
https://www.ncbi.nlm.nih.gov/pubmed/36588698
http://dx.doi.org/10.3389/fphar.2022.1076266

Ejemplares similares